The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline
- PMID: 34348321
- PMCID: PMC8678181
- DOI: 10.1159/000518581
The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline
Abstract
Background: Coronavirus disease 2019 (COVID-19), the far-reaching pandemic, has infected approximately 185 million of the world's population to date. After infection, certain groups, including older adults, men, and people of color, are more likely to have adverse medical outcomes. COVID-19 can affect multiple organ systems, even among asymptomatic/mild severity individuals, with progressively worse damage for those with higher severity infections.
Summary: The COVID-19 virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily attaches to cells through the angiotensin-converting enzyme 2 (ACE2) receptor, a universal receptor present in most major organ systems. As SARS-CoV-2 binds to the ACE2 receptor, its bioavailability becomes limited, thus disrupting homeostatic organ function and inducing an injury cascade. Organ damage can then arise from multiple sources including direct cellular infection, overactive detrimental systemic immune response, and ischemia/hypoxia through thromboembolisms or disruption of perfusion. In the brain, SARS-CoV-2 has neuroinvasive and neurotropic characteristics with acute and chronic neurovirulent potential. In the cardiovascular system, COVID-19 can induce myocardial and systemic vascular damage along with thrombosis. Other organ systems such as the lungs, kidney, and liver are all at risk for infection damage. Key Messages: Our hypothesis is that each injury consequence has the independent potential to contribute to long-term cognitive deficits with the possibility of progressing to or worsening pre-existing dementia. Already, reports from recovered COVID-19 patients indicate that cognitive alterations and long-term symptoms are prevalent. This critical review highlights the injury pathways possible through SARS-CoV-2 infection that have the potential to increase and contribute to cognitive impairment and dementia.
Keywords: Cognitive decline; Coronavirus disease 2019; Dementia risk; Neurological symptoms; Severe acute respiratory syndrome coronavirus 2.
© 2021 S. Karger AG, Basel.
Conflict of interest statement
In the past 3 years, Dr. Brickman has received paid compensation for consultation or advisory activities to Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Cognition Therapeutics, Inc., and Albert Einstein College of Medicine. He owns stock in Venus Medtech via Mars Holding Company. Dr. Brickman has a US patent (US9867566B2) and a patent pending (US20180228422A1), and has a copyrighted neuropsychological test instrument. His work has been supported by the US National Institutes of Health and Mars Symbioscience.
Figures
References
-
- Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5((9)):735–41. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
